Literature DB >> 9148020

Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1.

T Orth1, G Gerken, R Kellner, K H Meyer zum Büschenfelde, W J Mayet.   

Abstract

BACKGROUND/AIM: Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies first associated with Wegener's granulomatosis and microscopic polyangiitis. The significance of ANCA in autoimmune hepatitis remains uncertain; the nature of the antigen or antigens has not been defined yet. The purpose of this study was to identify the target antigen of ANCA in patients with autoimmune hepatitis. METHODS/
RESULTS: Sera from 32 type-1 autoimmune hepatitis patients were used in the present study. ANCA were detected in 24 of 32 sera (75%). A diffuse cytoplasmic staining pattern (C-ANCA) was detected in 14 patients; the P-ANCA pattern was observed in 10 patients. An extract of human neutrophils was prepared and subjected to SDS-PAGE and Western Blot analysis. A 43-kD dominant immunoreactive protein was found in 20 (63%) autoimmune hepatitis patients. Aminoacid sequence analysis of the 43 kD protein identified actin. Cytoplasmic or perinuclear staining pattern could be reduced after absorption of sera with actin and after removing anti-actin antibodies by affinity chromatography. This was observed for all C-ANCA and for 8 out of 10 P-ANCA. Moreover in double-staining indirect immunofluorescence, the same type of diffuse cytoplasmic staining was observed with autoimmune hepatitis-sera and anti-actin antibodies. In Western Blot analysis with actin, 17 (53%) patients gave a positive result, while 15 (47%) patients had a positive actin-ELISA.
CONCLUSION: This is the first report to identify the cytoskeletal protein actin as an ANCA antigen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148020     DOI: 10.1016/s0168-8278(97)80007-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

3.  Improved diagnoses of autoimmune hepatitis using an anti-actin ELISA.

Authors:  Vincent Aubert; Isabelle Graf Pisler; François Spertini
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

4.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

5.  Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection.

Authors:  Y-Y Wu; T-C Hsu; T-Y Chen; T-C Liu; G-Y Liu; Y-J Lee; G J Tsay
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

6.  High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis.

Authors:  J Sobajima; S Ozaki; H Uesugi; F Osakada; M Inoue; Y Fukuda; H Shirakawa; M Yoshida; A Rokuhara; H Imai; K Kiyosawa; K Nakao
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

7.  Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.

Authors:  Kalliopi Zachou; Eirini Rigopoulou; George N Dalekos
Journal:  J Autoimmune Dis       Date:  2004-10-15

Review 8.  Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

Authors:  Takashi Himoto; Mikio Nishioka
Journal:  Auto Immun Highlights       Date:  2013-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.